Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zika vaccine (gorilla adenovirus)
- Development stage
- Discontinued
- Lead developer
- GSK
- Modality
- Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The Zika vaccine (gorilla adenovirus) is a preclinical-stage viral vector vaccine candidate developed by Precigen (formerly Intrexon) in collaboration with Harvest Fund Management. The vaccine utilizes a gorilla-derived adenoviral (GRAd) vector to deliver genetic sequences encoding Zika virus antigens, specifically the pre-membrane (prM) and envelope (E) proteins. By expressing these antigens in vivo, the vaccine is designed to elicit both neutralizing antibodies and cellular immune responses to protect against Zika virus infection. Although early research demonstrated immunogenicity and protection in animal models, the program is currently considered a discontinued or early-stage research asset and is not part of Precigen's active clinical development pipeline.
- Other names
- gorilla adenovirus-based Zika vaccineZika genetic vaccine
02
Targets
ZIKV E (Zika virus envelope protein)prM (Zika virus precursor membrane protein)
Beyond the preview
Go deeper on zika vaccine (gorilla adenovirus).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zika vaccine (gorilla adenovirus).